Indeed, the IDH mutation (mIDH) has been identified as an early event in gliomagenesis preceding secondary and tertiary genetic alterations [11, 12], retained during progression [13–15] and remarkably ubiquitously expressed by tumor cells, including infiltrating single cells [16–19]. Here, IDH1 is linked to neoplasm.